Post Author: Hirva Mamdani, MD
Hirva Mamdani is the leader of the Thoracic Oncology Multidisciplinary Team, a member of the Phase I Clinical-Pharmacology Program, and director of the Lung Cancer Screening Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, an NCI-designated comprehensive cancer institute with 16 cancer treatment locations in Michigan and Ohio. She can be reached on Twitter @HirvaMamdani and on LinkedIn.
She specializes in the treatment of lung cancer, mesothelioma, and thymic cancer and leads multiple clinical trials. Her research interests include the development of treatment strategies for lung cancer to overcome resistance to immunotherapy.
Dr. Mamdani is the co-principal investigator of a study evaluating racial disparities in efficacy and toxicity of immunotherapy in patients with non-small cell lung cancer funded by P20 Specialized Program of Research Excellence (SPORE) award. She is the recipient of several young investigator awards and serves on the American Society of Clinical Oncology Expert Panel for developing treatment guidelines for advanced non-small-cell lung cancer.
She is the co-author of “Immunotherapy in Lung Cancer: Current Landscape and Future Directions” and “Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer.”
Hirva Mamdani is the leader of the Thoracic Oncology Multidisciplinary Team, a member of the Phase I Clinical-Pharmacology Program, and director of the Lung Cancer Screening Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, an NCI-designated comprehensive cancer institute with 16 cancer treatment locations in Michigan and Ohio. She can be reached on Twitter @HirvaMamdani and on LinkedIn.
She specializes in the treatment of lung cancer, mesothelioma, and thymic cancer and leads multiple clinical trials. Her research interests include the development of treatment strategies for lung cancer to overcome resistance to immunotherapy.
Dr. Mamdani is the co-principal investigator of a study evaluating racial disparities in efficacy and toxicity of immunotherapy in patients with non-small cell lung cancer funded by P20 Specialized Program of Research Excellence (SPORE) award. She is the recipient of several young investigator awards and serves on the American Society of Clinical Oncology Expert Panel for developing treatment guidelines for advanced non-small-cell lung cancer.
She is the co-author of "Immunotherapy in Lung Cancer: Current Landscape and Future Directions" and "Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer."
Why does one person respond favorably to lung cancer treatment while another does not?
The answer lies in their DNA.
Just 20 years ago, lung cancer was broadly categorized into two groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Relatively recently, the treatment of NSCLC shifted from chemotherapy as a single treatment option to treatment with precision medicine, which is positively impacting survival rates.
Read more…
